Overview
Calcium alpha-ketoglutarate (Ca-AKG) is an increasingly studied supplement that combines calcium with alpha-ketoglutarate, a naturally occurring compound that plays a critical role in cellular energy metabolism. Alpha-ketoglutarate is a key intermediate in the Krebs cycle—the fundamental biochemical pathway that generates energy in your cells—and has emerged as a research target for supporting longevity, healthspan extension, and metabolic resilience.
Unlike many trendy supplements, Ca-AKG has a credible mechanistic foundation. It acts as a cofactor for over 60 enzymes involved in DNA regulation, collagen synthesis, and cellular signaling. Growing scientific interest centers on its potential to compress morbidity (the period of ill health before death) and extend healthspan—the years of healthy, functional life—rather than simply living longer.
This supplement is taken orally at doses ranging from 1,000–3,000 mg daily and costs approximately $25–$75 per month, making it relatively affordable for those interested in longevity-focused interventions.
How It Works: Mechanism of Action
Alpha-ketoglutarate functions as a metabolic hub, influencing aging and gene expression through multiple pathways:
Krebs Cycle and Cellular Energy
As a Krebs cycle intermediate, alpha-ketoglutarate is essential for ATP (cellular energy) production. It sits at a branch point where the cell decides whether to prioritize energy generation or biosynthesis (building new molecules). This positioning makes it a sensitive regulator of metabolic fate.
Epigenetic Regulation and DNA Methylation
Ca-AKG acts as a cofactor for TET enzymes and histone demethylases (KDMs), which remove methyl marks from DNA and histone proteins. These epigenetic modifications are central to aging and gene expression regulation. By supporting these enzymes, Ca-AKG may help maintain healthier epigenetic patterns associated with younger biological ages.
mTOR and Caloric Restriction Mimicry
Alpha-ketoglutarate competitively inhibits ATP synthase and modulates mTOR signaling—pathways central to cellular aging. This mechanism suggests Ca-AKG may mimic some benefits of caloric restriction at the cellular level without requiring actual calorie reduction.
Nitrogen Scavenging and Amino Acid Metabolism
Ca-AKG acts as a nitrogen scavenger, facilitating amino acid transamination and serving as a precursor for glutamate and proline. Proline is critical for collagen biosynthesis, the structural protein essential for skin, joints, and connective tissues. It also supports gut mucosal integrity, which is vital for immune function and metabolic health.
Evidence by Health Goal
Longevity & Biological Aging — Tier 3
What Tier 3 Means: Promising human evidence with clear mechanistic support, but limited to small studies lacking independent replication.
The most compelling human evidence for Ca-AKG centers on biological aging. In a study of 42 humans taking Rejuvant® (an AKG-based formulation), DNA methylation age—a molecular clock that predicts aging rate and mortality risk—decreased by an average of 8 years after 7 months (p=6.538×10⁻¹²). This is a substantial finding, though the study was retrospective and relatively small.
The ABLE trial, an ongoing randomized controlled trial involving 120 middle-aged adults, is testing whether 1 gram daily of sustained-release Ca-AKG reduces DNA methylation age over 6 months in individuals with elevated biological age. Results from this rigorous study may substantially strengthen evidence for this application.
Bottom Line: Ca-AKG shows genuine promise for slowing biological aging markers in humans, but evidence remains limited to small, short-term studies. Independent replication is needed.
Anti-Inflammation — Tier 2
What Tier 2 Means: Promising mechanistic and animal evidence, but inadequate human RCT data to prove efficacy.
In animal models, alpha-ketoglutarate demonstrates clear anti-inflammatory effects. In mice exposed to water-immersion restraint stress, alpha-ketoglutarate pretreatment reduced TNF-α and IL-1β expression (inflammatory cytokines), decreased myeloperoxidase levels (a marker of immune activation), and preserved glutathione (a master antioxidant) compared to stress-only controls.
In humans, a small RCT (n=21) found that alpha-ketoglutarate increased glucuronate and UDP-glucuronate—molecules involved in detoxification and immune regulation. These metabolic changes are associated with reduced systemic inflammation, though direct inflammatory markers were not reported.
Bottom Line: Mechanistically plausible for reducing inflammation, but human evidence remains indirect. More rigorous RCTs are needed.
Injury Recovery — Tier 2
What Tier 2 Means: Consistent promise in animal models but limited human evidence.
Animal studies are encouraging: in aged mice (18 months old), AKG administration increased bone mass, attenuated age-related bone loss, accelerated bone regeneration, and reversed senescence-associated phenotypes in bone marrow mesenchymal stem cells.
However, human evidence consists of a single RCT on pressure ulcers (n=160). Patients receiving oral ketoglutarate (OKG, a related compound) for 6 weeks showed ulcer area reduction, but the results were confounded by unequal baseline ulcer distribution (median 6.6 cm² vs. 3.9 cm²), which weakened confidence in the conclusions.
Bottom Line: Strong animal evidence for bone health and wound healing; single inconclusive human study on ulcers. More human research is essential.
Joint Health — Tier 2
What Tier 2 Means: Consistent animal evidence but no human clinical trials.
Alpha-ketoglutarate reversed IL-1β-induced decreases in collagen II, aggrecan, and Sox9 in mouse condylar chondrocytes—key markers of cartilage health. In studies of aged mice, α-KG improved overall cartilage health.
In rat models of intervertebral disc degeneration, AKG reduced senescence markers (p16, p53) and inhibited JAK2/STAT3 phosphorylation, ameliorating disc degeneration in vivo.
Bottom Line: Consistent animal evidence supporting joint and cartilage health through collagen-preserving and anti-senescence mechanisms. No human trials exist; efficacy in humans remains plausible but unproven.
Immune Support — Tier 2
What Tier 2 Means: Plausible mechanistic support and limited animal evidence, but absent robust human trials.
In a small human RCT (n=20) using a formula containing α-KG pathway support (glutathione + resveratrol precursors), neopterin (an inflammatory marker) significantly decreased and antioxidant vitamins C, E, and A increased after 8 weeks.
In immune-challenged ants, fertile workers specifically upregulated α-ketoglutarate synthesis genes, linking α-KG to immune response regulation and extended lifespan.
Bottom Line: Plausible immune-supportive effects based on mechanistic pathways, but direct human clinical evidence for Ca-AKG specifically is absent.
Energy Metabolism — Tier 2
What Tier 2 Means: Mechanistically plausible with some animal support, but lacking rigorous human evidence.
Alpha-ketoglutarate showed mixed results in Drosophila (fruit fly) models. It did not extend lifespan or improve climbing activity, heat stress resistance, or starvation resistance in long-lived fruit flies on a normal diet. However, on a low-protein diet, it did increase lifespan, suggesting its effects may be diet-dependent.
No human trials have directly measured energy levels, fatigue, or physical performance with Ca-AKG supplementation as the primary intervention.
Bottom Line: Mechanistically sound for energy metabolism, but human efficacy for improving energy or exercise performance remains undemonstrated.
Skin & Hair — Tier 2
What Tier 2 Means: Plausible mechanisms with animal and in-vitro support, but no rigorous human trials.
Alpha-ketoglutarate stimulated procollagen production by 25.6% ± 4.6% in cultured human dermal fibroblasts at 10 μM versus vehicle control. Topical 1% α-ketoglutarate application decreased UVB-induced wrinkle formation in hairless mice over 12 weeks compared to vehicle, though exact wrinkle reduction percentages were not reported.
Bottom Line: In-vitro and animal evidence supports collagen-boosting potential for skin health. Human efficacy studies are needed.
Muscle Growth — Tier 2
What Tier 2 Means: Historical interest with no recent human evidence.
Historical studies from the 1980s–1990s suggested potential benefits of αKG for muscle growth, but no recent human trials demonstrating efficacy exist. Animal models show promise: in D-galactose-induced aging mice, alpha-ketoglutarate significantly improved muscle mass, grip strength, exercise endurance, and cold tolerance compared to controls.
Bottom Line: Animal evidence is encouraging, but no human trials support muscle growth benefits.
Cognition — Tier 1
What Tier 1 Means: No demonstrated efficacy in humans; mechanistic interest only.
A single human RCT (n=80, double-blind, 8 weeks) tested CAAKG in a pre-workout supplement for cognitive effects using the Stroop Test (a measure of attention and processing speed). Results showed no statistically significant effects versus placebo.
Observationally, α-ketoglutarate dehydrogenase complex activity is decreased 57% in Alzheimer's disease brain tissue and correlates with clinical disability (r=0.77), suggesting a potential link between AKG metabolism and cognitive decline. However, this finding does not prove that AKG supplementation improves cognition.
Bottom Line: No human evidence supports cognitive benefits; mechanistic interest exists but lacks clinical validation.
Mood & Stress — Tier 1
What Tier 1 Means: No human studies; mechanistic interest only.
Ca-AKG has not been studied for mood, anxiety, depression, or stress outcomes in humans. One mouse study found that alpha-ketoglutarate reduced inflammatory markers (TNF-α, IL-1β) and restored antioxidant glutathione in water-immersion restraint stress, but this measured tissue damage prevention, not mood or behavioral stress responses.
Bottom Line: No human evidence exists for mood or stress benefits.
Sleep — Tier 1
What Tier 1 Means: No human or animal studies testing this outcome.
Zero human RCTs and zero animal studies directly testing Ca-AKG for sleep have been identified in the literature.
Bottom Line: No evidence exists.
Fat Loss — Tier 1
What Tier 1 Means: No human studies testing Ca-AKG as a weight loss intervention.
Ca-AKG has not been studied for fat loss in humans. Research has identified the FTO gene as a genetic locus associated with obesity risk and shown that FTO rs9939609 A-allele carriers have higher BMI and dietary protein intake, but this is genetics research, not supplementation trials.
Bottom Line: No evidence supports fat loss claims.
Gut Health — Tier 1
What Tier 1 Means: No human efficacy data; animal and mechanistic studies only.
In fattening lambs (n=18, animal study), the calcium salt of AKG increased rumen butyrate concentration, total volatile fatty acid concentration, and digestibility of ether extract (P<0.05). However, no human trials testing Ca-AKG for gut health outcomes exist.
Bottom Line: Plausible mechanism through collagen and gut barrier support, but no human evidence.
Heart Health — Tier 1
What Tier 1 Means: No efficacy evidence; safety data only.
Ca-AKG has not been studied for heart health outcomes in humans. In one study where it was included in a pre-workout supplement (2 g dose) tested acutely in 25 healthy young adults with heart rate, blood pressure, and ECG measurements, no adverse cardiac effects were reported, but no efficacy for heart health was assessed.
Bottom Line: No evidence for or against; safety appears reasonable in healthy individuals.
Liver Health — Tier 1
What Tier 1 Means: No direct human evidence; animal and mechanistic studies only.
In mice with diet-induced NASH (nonalcoholic steatohepatitis), upregulation of SLC7A11 (which increases αKG production) alleviated hepatic steatohepatitis and fibrosis through ROS reduction and AMPK-mitophagy axis activation. In-vitro mitochondrial studies show αKG can effectively diminish reactive oxygen species (ROS) by being diverted away from standard metabolic oxidation.
Bottom Line: Mechanistically plausible; no human evidence exists.
Hormonal Balance — Tier 2
What Tier 2 Means: Some human evidence in specific populations; broader effects remain mechanistic.
Long-term Ca-AKG treatment (4.5 g/day for 36 months) normalized secondary hyperparathyroidism in dialysis patients: intact PTH decreased from 29±5 to 8±2 pmol/L (p<0.001), serum phosphate dropped from 2.6±0.1 to 1.9±0.07 mmol/L (p<0.001), and calcium-to-phosphate ratio improved from 0.91±0.02 to 1.28±0.01 (p<0.001) in an RCT (n=14).
A single-dose study in healthy males (n=6) found Ca-AKG (3.6 g) increased acute insulinemia by +24% at 15 minutes (p<0.05) and glucagonemia by +30% at 60 minutes (p<0.01).
Bottom Line: Clear benefits for mineral metabolism in dialysis patients; broader hormonal effects remain largely theoretical.
Sexual Health — Tier 2
What Tier 2 Means: Consistent animal evidence; no human RCTs.
AKG supplementation for 4 months in aging mice significantly increased follicle numbers and improved oocyte quality, with reduced fragmentation rate and ROS levels, plus lower abnormal spindle assembly rates. Long-term AKG administration in mice preserved ovarian function and maintained oocyte quality and quantity.
Notably, reduced α-KG levels have been observed in human follicle fluid with aging, suggesting a potential therapeutic target. However, no human RCTs testing AKG supplementation for fertility or sexual health exist.
Bottom Line: Promising animal evidence for ovarian health; no human efficacy data.
Athletic Performance — Tier 2
What Tier 2 Means: Animal evidence present; no direct human efficacy data.
In D-galactose-induced aging mice, alpha-ketoglutarate significantly improved muscle mass, grip strength, exercise endurance, and cold tolerance compared to controls. In mouse C2C12 myoblasts, AKG supplementation promoted cell proliferation and differentiation in both normal and low-glucose energy states through glutamine metabolism and oxidative stress reduction.
Two human RCTs included Ca-AKG as part of multi-ingredient pre-workout supplements, but results were not statistically significant. No study has tested Ca-AKG alone for athletic performance.
Bottom Line: Strong mechanistic and animal evidence; no human efficacy data for athletic performance specifically.